Jim Simons
AVIR icon

Jim Simons’s Atea Pharmaceuticals AVIR Stock Holding History

Jim Simons’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26M Sell
1,131,200
-35,200
-3% -$175K 0.01% 1436
2026
Q1 		$6.28M Sell
1,166,400
-22,100
-2% -$101K 0.01% 1230
2025
Q4 		$4.24M Sell
1,188,500
-39,400
-3% -$125K 0.01% 1396
2025
Q3 		$3.56M Sell
1,227,900
-6,200
-0.5% -$21.2K ﹤0.01% 1683
2025
Q2 		$4.44M Sell
1,234,100
-44,300
-3% -$132K 0.01% 1593
2025
Q1 		$3.82M Buy
1,278,400
+61,800
+5% +$193K 0.01% 1589
2024
Q4 		$4.08M Buy
1,216,600
+9,500
+0.8% +$31.6K 0.01% 1581
2024
Q3 		$4.04M Buy
1,207,100
+65,600
+6% +$238K 0.01% 1579
2024
Q2 		$3.78M Buy
1,141,500
+18,100
+2% +$67.5K 0.01% 1482
2024
Q1 		$4.54M Sell
1,123,400
-372,903
-25% -$1.46M 0.01% 1479
2023
Q4 		$4.56M Buy
1,496,303
+141,762
+10% +$429K 0.01% 1407
2023
Q3 		$4.06M Sell
1,354,541
-8,841
-0.6% -$30.1K 0.01% 1423
2023
Q2 		$5.1M Buy
1,363,382
+635,682
+87% +$2.38M 0.01% 1421
2023
Q1 		$2.44M Buy
727,700
+107,100
+17% +$434K ﹤0.01% 1902
2022
Q4 		$2.98M Buy
620,600
+23,200
+4% +$117K ﹤0.01% 1821
2022
Q3 		$3.4M Sell
597,400
-65,600
-10% -$502K ﹤0.01% 1683
2022
Q2 		$4.71M Sell
663,000
-502,000
-43% -$3.43M 0.01% 1610
2022
Q1 		$8.41M Buy
1,165,000
+544,200
+88% +$3.7M 0.01% 1232
2021
Q4 		$5.55M Buy
620,800
+598,200
+2,647% +$9.32M 0.01% 1466
2021
Q3 		$792K Buy
+22,600
New +$627K ﹤0.01% 2674

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Tang Capital Management
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jim Simons's AVIR Position: Q2 2026 in Review

Jim Simons reduced its Atea Pharmaceuticals (AVIR) stake by 3% in Q2 2026, selling an estimated $175K and leaving 1,131,200 shares worth $5.26M. The position accounts for 0.01% of the portfolio, ranked #1436.

Jim Simons first reported a position in AVIR in Q3 2021 and has held it in 20 quarters since. The position peaked at $8.41M in Q1 2022. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Jim Simons held 1,131,200 shares of Atea Pharmaceuticals worth $5.26M as of Q2 2026.
  • Jim Simons sold 35,200 Atea Pharmaceuticals shares in Q2 2026, an estimated $175K.
  • Atea Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1436 holding.
  • Jim Simons first reported a position in Atea Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Jim Simons's Atea Pharmaceuticals position peaked at $8.41M in Q1 2022.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.